SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
SEC Accession No. 0000950135-05-003515
Filing Date
2005-06-27
Accepted
2005-06-27 13:04:54
Documents
11
Effectiveness Date
2005-06-27

Document Format Files

Seq Description Document Type Size
1 TRANSKARYOTIC THERAPIES, INC. b55155dadefm14a.htm DEFM14A 1164456
3 GRAPHIC b55155dab5515506.gif GRAPHIC 808
4 GRAPHIC b55155dab5515508.gif GRAPHIC 3406
5 GRAPHIC b55155dab5515507.gif GRAPHIC 3586
6 GRAPHIC b55155dab5515500.gif GRAPHIC 1655
7 GRAPHIC b55155dab5515504.gif GRAPHIC 1425
8 GRAPHIC b55155dab5515503.gif GRAPHIC 1464
9 GRAPHIC b55155dab5515505.gif GRAPHIC 2997
10 GRAPHIC b55155dab5515509.gif GRAPHIC 3273
11 GRAPHIC b55155dab5515510.gif GRAPHIC 2779
12 GRAPHIC b55155dab5515511.gif GRAPHIC 2888
  Complete submission text file 0000950135-05-003515.txt   1200765
Mailing Address
Business Address 195 ALBANY ST CAMBRIDGE MA 02139 6173490200
TRANSKARYOTIC THERAPIES INC (Filer) CIK: 0000885259 (see all company filings)

IRS No.: 043027191 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFM14A | Act: 34 | File No.: 000-21481 | Film No.: 05916938
SIC: 2836 Biological Products, (No Diagnostic Substances)